Metabolic and molecular imaging in neuro-oncology

Lancet Neurology

Volumn 6, Issue 8, 2007, Pages 711-724

  Herholz, Karl ^a   Coope, David ^a   Jackson, Alan ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

DNA SYNTHESIS; ENERGY METABOLISM; GLUCOSE INTAKE; IN VIVO STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW;

BRAIN NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; METABOLIC NETWORKS AND PATHWAYS;

EID: 34447345366     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70192-8     Document Type: Review

References (180)

1. Reivich M., Kuhl D., Wolf A., et al. Measurement of local cerebral glucose metabolism in man with 18F- 2-fluoro-2-deoxy-D-glucose. Acta Neurol Scand 64 suppl (1977) 190-191
2. Negendank W. Studies of human tumors by MRS: a review. NMR in Biomedicine 5 (1992) 303-324
3. Gelovani T., and Blasberg R. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 3 (2003) 327-332
4. Jacobs A., Li H., Winkeler A., et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging 30 (2003) 1051-1065
5. Provenzale J., Mukundan S., and Barboriak D. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 239 (2006) 632-649
6. Sunaert S. Presurgical planning for tumor resectioning. J Magn Reson Imaging 23 (2006) 887-905
7. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol 4 (2005) 476-486
8. Weissleder R. Molecular imaging in cancer. Science 312 (2006) 1168-1171
9. Massoud T., and Gambhir S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
10. Kleihues P., Louis D., Scheithauer B., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (2002) 215-225
11. Law M., Oh S., Babb J., et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 238 (2006) 658-667
12. Fan G., Deng Q., Wu Z., and Guo Q. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?. British Journal of Radiology 79 (2006) 652-658
13. Patankar T., Haroon H., Mills S., et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. Am J Neuroradiol 26 (2005) 2455-2465
14. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol; 26: 777-83.
15. Lupo J., Cha S., Chang S., and Nelson S. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol 26 (2005) 1446-1454
16. Mills S., Patankar T., Haroon H., Baleriaux D., Swindell R., and Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. Am J Neuroradiol 27 (2006) 853-858
17. Stadlbauer A., Ganslandt O., Buslei R., et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 240 (2006) 803-810
18. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9 (1999) 53-60
19. Bode M., Ruohonen J., Nieminen M., and Pyhtinen J. Potential of diffusion imaging in brain tumors: a review. Acta Radiol 47 (2006) 585-594
20. Cairncross J., Ueki K., Zlatescu M., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
21. Ino Y., Betensky R., Zlatescu M., et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7 (2001) 839-845
22. Aghi M., Gaviani P., Henson J., Batchelor T., Louis D., and Barker II F. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11 (2005) 8600-8605
23. Tofts P. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7 (1997) 91-101
24. Jackson A. Analysis of dynamic contrast enhanced MRI. Br J Radiol 77 (2004) S154-S166
25. Wintermark M., Sesay M., Barbier E., et al. Comparative overview of brain perfusion imaging techniques. Stroke 36 (2005) e83-e99
26. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27 (2006) 475-487
27. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24 (2003) 1989-1998
28. Muzi M., Freeman S., Burrows R., et al. Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nucl Med Biol 28 (2001) 107-116
29. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46 (2005) 675-682
30. Majewski N., Nogueira V., Bhaskar P., et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16 (2004) 819-830
31. Bos R., van Der Hoeven J., van Der Wall E., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
32. Herholz K., Rudolf J., and Heiss W. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 12 (1992) 159-165
33. Meyer P., Schreckenberger M., Spetzger U., et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 28 (2001) 165-174
34. Kim C., Alavi J., Alavi A., and Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 10 (1991) 85-91
35. Wienhard K., Pawlik G., Herholz K., Wagner R., and Heiss W. Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures. J Cereb Blood Flow Metab 5 (1985) 115-125
36. Krohn K., Mankoff D., Muzi M., Link J., and Spence A. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32 (2005) 663-671
37. Alavi J., Alavi A., Chawluk J., et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62 (1988) 1074-1078
38. Di Chiro G., DeLaPaz R., Brooks R., et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32 (1982) 1323-1329
39. Barker F., Chang S., Valk P., Pounds T., and Prados M. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79 (1997) 11526
40. Patronas N., Di Chiro G., Kufta C., et al. Prediction of survival in glioma patients by means of positron emission tomography. Journal Neurosurg 62 (1985) 816-822
41. Delbeke D., Meyerowitz C., Lapidus R., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195 (1995) 47-52
42. Holthoff V., Herholz K., Berthold F., et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 72 (1993) 1394-1403
43. Okada J., Yoshikawa K., Imazeki K., et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 32 (1991) 686-691
44. Basso U., and Brandes A. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. Eur J Cancer 38 (2002) 1298-1312
45. Hoffman J., Waskin H., Schifter T., et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 34 (1993) 567-575
46. Borbely K., Fulham M., Brooks R., and Di Chiro G. PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med 33 (1992) 1931-1934
47. DeLaPaz R., Patronas N., Brooks R., et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. Am J Neuroradiol 4 (1983) 826-829
48. Holzer T., Herholz K., Jeske J., and Heiss W. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogry 17 (1993) 681-687
49. Roelcke U., Blasberg R., von A., et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39 (1998) 879-884
50. Fulham M., Brunetti A., Aloj L., Raman R., Dwyer A., and Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 83 (1995) 657-664
51. Ishizu K., Nishizawa S., Yonekura Y., et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 35 (1994) 1104-1109
52. Wienhard K., Pawlik G., Nebeling B., et al. Estimation of local cerebral glucose utilization by positron emission tomography: comparison of [18F]2-fluoro-2-deoxy-D-glucose and [18F]2-fluoro-2-deoxy-D-mannose in patients with focal brain lesions. J Cereb Blood Flow Metab 11 (1991) 485-491
53. Uehara H., Miyagawa T., Tjuvajev J., et al. Imaging experimental brain tumors with 1-aminocyclopentane carboxylic acid and alpha-aminoisobutyric acid: comparison to fluorodeoxyglucose and diethylenetriaminepentaacetic acid in morphologically defined tumor regions. J Cereb Blood Flow Metab 17 (1997) 1239-1253
54. Mosskin M., Bergstrom M., Collins V., et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiologica 369 suppl (1986) 157-160
55. Bergstrom M., Ericson K., Hagenfeldt L., et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 11 (1987) 208-213
56. Killian D., and Chikhale P. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. Neurosc Lett 306 (2001) 1-4
57. Miyagawa T., Oku T., Uehara H., et al. Facilitated" amino acid transport is upregulated in brain tumors. J Comput Assist Tomogr 18 (1998) 500-509
58. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 50 (1998) 1316-1322
59. Roelcke U., Radu E., Ametamey S., Pellikka R., Steinbrich W., and Leenders K. Association of 82Rubidium and 11C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 27 (1996) 163-171
60. Chung J., Kim Y., Kim S., et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29 (2002) 176-182
61. Sato N., Suzuki M., Kuwata N., et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22 (1999) 210-214
62. Kracht L., Friese M., Herholz K., et al. Methyl-[(11)C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30 (2003) 868-873
63. Weber W., Wester H., Grosu A., et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med Mol Imaging 27 (2000) 542-549
64. Weckesser M., Langen K., Rickert C., et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 32 (2005) 422-429
65. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128 (2005) 678-687
66. Langen K., Ziemons K., Kiwit J., et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38 (1997) 517-522
67. 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 70 (2004) 49-58
68. Derlon J., Chapon F., Noel M., et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27 (2000) 778-787
69. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med 47 (2006) 393-403
70. De Witte O., Goldberg I., Wikler D., et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95 (2001) 746-750
71. Ribom D., Eriksson A., Hartman M., et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 92 (2001) 1541-1549
72. Mankoff D., Shields A., Link J., et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med 40 (1999) 614-624
73. Shields A., Grierson J., Dohmen B., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
74. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 (2005) 1948-1958
75. 18F-fluorothymidine in patients with gliomas. J Nucl Med 47 (2006) 1612-1621
76. Schwartz J., Tamura Y., Jordan R., Grierson J., and Krohn K. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44 (2003) 2027-2032
77. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 31 (2004) 169-178
78. Muzi M., Vesselle H., Grierson J., et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 46 (2005) 274-282
79. Kenny L., Vigushin D., Al-Nahhas A., et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65 (2005) 10104-10112
80. 18F-FDG PET in esophageal cancer. J Nucl Med 46 (2005) 400-404
81. Moller-Hartmann W., Herminghaus S., Krings T., et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44 (2002) 371-381
82. Herholz K., Heindel W., Luyten P., et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 31 (1992) 319-327
83. Maintz D., Heindel W., Kugel H., Jaeger R., and Lackner K. Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours. NMR Biomed 15 (2002) 18-27
84. 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 22 (2002) 1523-1531
85. Bink A., Gaa J., Franz K., et al. Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralblatt fur Neurochirurgie 66 (2005) 119-125
86. Mascalchi M., Filippi M., Floris R., Fonda C., Gasparotti R., and Villari N. Diffusion-weighted MR of the brain: methodology and clinical application. Radiologia Medica 109 (2005) 155-197
87. Erdogan C., Hakyemez B., Yildirim N., and Parlak M. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility contrast perfusion-weighted MRI. J Comput Assist Tomogr 29 (2005) 663-667
88. Holmes T., Petrella J., and Provenzale J. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. AJR Am J Roentgenol 183 (2004) 1247-1252
89. Law M., Hamburger M., Johnson G., et al. Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat 3 (2004) 557-565
90. Calli C., Kitis O., Yunten N., Yurtseven T., Islekel S., and Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 58 (2006) 394-403
91. Hartmann M., Heiland S., Harting I., et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338 (2003) 119-122
92. Kremer S., Grand S., Remy C., et al. Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma. Neuroradiology 46 (2004) 642-648
93. Yamasaki F., Kurisu K., Satoh K., et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235 (2005) 985-991
94. Yang S., Law M., Zagzag D., et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol 24 (2003) 1554-1559
95. Cha S., Tihan T., Crawford F., et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26 (2005) 266-273
96. 1H MRS of human brain abscesses in vivo and in vitro. Magn Reson Med 34 (1995) 508-514
97. Mishra A., Gupta R., Jaggi R., et al. Role of diffusion-weighted imaging and in vivo proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing intracranial cystic mass lesions. J Comput Assist Tomogr 28 (2004) 540-547
98. Cho Y., Choi G., Lee S., and Kim J. (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magn Reson Imaging 21 (2003) 663-672
99. Hazany S., Hesselink J., Healy J., and Imbesi S. Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 49 (2007) 121-127
100. Jackson R., Fuller G., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 3 (2001) 193-200
101. Hanson M., Glantz M., Hoffman J., et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 15 (1991) 796-801
102. 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45 (2004) 1293-1298
103. Aronen H., Pardo F., Kennedy D., et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 6 (2000) 2189-2200
104. Cha S., Knopp E., Johnson G., Wetzel S., Litt A., and Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223 (2002) 11-29
105. Pirotte B., Goldman S., Dewitte O., et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 104 (2006) 238-253
106. Stieltjes B., Schluter M., Didinger B., et al. Diffusion tensor imaging in primary brain tumors: reproducible quantitative analysis of corpus callosum infiltration and contralateral involvement using a probabilistic mixture model. Neuroimage 31 (2006) 531-542
107. Croteau D., Scarpace L., Hearshen D., et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 49 (2001) 823-829
108. Patronas N., Di Chiro G., Smith B., et al. Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Res 291 (1984) 93-101
109. Vajkoczy P., Goldbrunner R., Farhadi M., et al. Glioma cell migration is associated with glioma-induced angiogenesis in vivo. Int J Dev Neurosci 17 (1999) 557-563
110. Kracht L., Miletic H., Busch S., et al. Brain tumor extent with [11C]-L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10 (2004) 7163-7170
111. Stummer W., Pichlmeier U., Meinel T., Wiestler O., Zanella F., and Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7 (2006) 392-401
112. 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 64-74
113. Jena R., Price S., Baker C., et al. Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. Clin Oncol (R Coll Radiol) 17 (2005) 581-590
114. Tyler J., Diksic M., Villemure J., et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28 (1987) 1123-1133
115. Rhodes C., Wise R., Gibbs J., et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14 (1983) 614-626
116. 11CO2 and positron emission tomography. J Cereb Blood Flow Metab 6 (1986) 529-535
117. Rottenberg D., Ginos J., Kearfott K., Junck L., Dhawan V., and Jarden J. In vivo measurement of brain tumor pH using [11C]DMO and positron emission tomography. Ann Neurol 17 (1985) 70-79
118. Horowitz M., Blasberg R., Molnar P., et al. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors. Cancer Res 43 (1983) 3800-3807
119. 18F-FDG PET, and immunohistochemical studies. J Nuclear Med 47 (2006) 410-418
120. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nuclear Med 46 (2005) 253-260
121. Rischin D., Hicks R., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
122. Ribom D., Engler H., Blomquist E., and Smits A. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med 29 (2002) 632-640
123. Imahori Y., Ueda S., Ohmori Y., et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res 4 (1998) 1825-1832
124. Hamstra D., Chenevert T., Moffat B., et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102 (2005) 16759-16764
125. Moffat B., Chenevert T., Lawrence T., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102 (2005) 5524-5529
126. Mabbott D., Noseworthy M., Bouffet E., Rockel C., and Laughlin S. Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ. Neuro-oncol 8 (2006) 244-252
127. Kahkonen M., Metsahonkala L., Minn H., et al. Cerebral glucose metabolism in survivors of childhood acute lymphoblastic leukemia. Cancer 88 (2000) 693-700
128. Schiffer D., Giordana M., Soffietti R., and Sciolla R. Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. Acta Neuropathol 58 (1982) 291-299
129. Di Chiro G., Oldfield E., Wright D., et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 150 (1988) 189-197
130. Ricci P., Karis J., Heiserman J., Fram E., Bice A., and Drayer B. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 19 (1998) 407-413
131. 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir 38 (1998) 342-347
132. Tsuyuguchi N., Takami T., Sunada I., et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma. Ann Nucl Med 18 (2004) 291-296
133. Rachinger W., Goetz C., Popperl G., et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57 (2005) 505-511
134. Rock J., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54 (2004) 1111-1117
135. Chan Y., Yeung D., Leung S., and Chan P. Diffusion-weighted magnetic resonance imaging in radiation-induced cerebral necrosis. Apparent diffusion coefficient in lesion components. J Comput Assist Tomogr 27 (2003) 67480
136. Hein P., Eskey C., Dunn J., and Hug E. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR. American J Neuroradiol 25 (2004) 201-209
137. Leach M., Brindle K., Evelhoch J., et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 76 suppl 1 (2003) S87-S91
138. Iannotti F., Fieschi C., Alfano B., et al. Simplified, noninvasive PET measurement of blood-brain barrier permeability. J Comput Assist Tomogr 11 (1987) 390-397
139. Hawkins R., Phelps M., Huang S., et al. A kinetic evaluation of blood-brain barrier permeability in human brain tumors with [68Ga]EDTA and positron computed tomography. J Cereb Blood Flow Metab 4 (1984) 507-515
140. Yen C., Yano Y., Budinger T., et al. Brain tumor evaluation using Rb-82 and positron emission tomography. J Nucl Med 23 (1982) 532-537
141. Roelcke U., Radu E., von Ammon K., Hausmann O., Maguire R., and Leenders K. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Scis 132 (1995) 20-27
142. Jarden J. Pathophysiological aspects of malignant brain tumors studied with positron emission tomography. Acta Neurol Scand 156 suppl (1994) 1-35
143. 82Rb: the effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 18 (1985) 636-646
144. Kessler R., Goble J., Bird J., et al. Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. J Cereb Blood Flow Metab 4 (1984) 323-328
145. Zunkeler B., Carson R., Olson J., et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 85 (1996) 1056-1065
146. Zunkeler B., Carson R., Olson J., et al. Hyperosmolar blood-brain barrier disruption in baboons-an in vivo study using positron emission tomography and Rubidium-82. J Neurosurg 84 (1996) 494-502
147. Brock C., Young H., O'Reilly S., et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82 (2000) 608-615
148. Charnley N., West C., Barnett C., et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 331-338
149. 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33 (2006) 516-524
150. Murphy P., Viviers L., Abson C., et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 90 (2004) 781-786
151. Popperl G., Goldbrunner R., Gildehaus F., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32 (2005) 1018-1025
152. Jacobs A., Voges J., Reszka R., et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
153. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol 10 (1991) 47-55
154. Diksic M., Sako K., Feindel W., et al. Pharmacokinetics of positron-labeled 1,3-bis(2- chloroethyl)nitrosourea in human brain tumors using positron emission tomography. Cancer Research 44 (1984) 3120-3124
155. Meikle S., Matthews J., Brock C., et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 42 (1998) 183-193
156. Saleem A., Brown G., Brady F., et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63 (2003) 2409-2415
157. Tyler J., Yamamoto Y., Diksic M., et al. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med 27 (1986) 775-780
158. Brix G., Bellemann M., Gerlach L., and Haberkorn U. Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 209 (1998) 259-267
159. Piwnica-Worms D., Kesarwala A., Pichler A., Prior J., and Sharma V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein-monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin N Am 16 (2006) 575-589
160. Lee K., Hall D., Hoff B., et al. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 66 (2006) 4687-4692
161. Jager H., Waldman A., Benton C., Fox N., and Rees J. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 26 (2005) 274-278
162. Collingridge D., Carroll V., Glaser M., et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 (2002) 5912-5919
163. Jayson G., Zweit J., Jackson A., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94 (2002) 1484-1493
164. Velikyan I., Sundberg A., Lindhe O., et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46 (2005) 1881-1888
165. Jacobs A., Tjuvajev J., Dubrovin M., et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 61 (2001) 2983-2995
166. Buursma A., Beerens A., de Vries E., et al. The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J Nucl Med 46 (2005) 2068-2075
167. Hung S., Deng W., Yang W., et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by non-invasive in vivo positron emission tomography imaging. Clin Cancer Res 11 (2005) 7749-7756
168. Frank J., Miller B., Arbab A., et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 228 (2003) 480-487
169. Martina M., Fortin J., Menager C., et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc 127 (2005) 10676-10685
170. Rubesova E., Berger F., Wendland M., et al. Gd-labeled liposomes for monitoring liposome-encapsulated chemotherapy: quantification of regional uptake in tumor and effect on drug delivery. Acad Radiol 9 suppl 2 (2002) S525-S527
171. Shinkai M., and Ito A. Functional magnetic particles for medical application. Adv Biochem Eng Biotechnol 91 (2004) 191-220
172. Fossheim S., Il'yasov K., Hennig J., and Bjornerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad Radiol 7 (2000) 1107-1115
173. Lokling K., Fossheim S., Skurtveit R., Bjornerud A., and Klaveness J. pH-sensitive paramagnetic liposomes as MRI contrast agents: in vitro feasibility studies. Magn Reson Imaging 19 (2001) 731-738
174. Lokling K., Skurtveit R., Dyrstad K., Klaveness J., and Fossheim S. Tuning the MR properties of blood-stable pH-responsive paramagnetic liposomes. Int J Pharm 274 (2004) 75-83
175. Lokling K., Skurtveit R., Fossheim S., Smistad G., Henriksen I., and Klaveness J. pH-sensitive paramagnetic liposomes for MRI: assessment of stability in blood. Magn Reson Imaging 21 (2003) 531-540
176. Bulte J., and De Cuyper M. Magnetoliposomes as contrast agents. Methods Enzymol 373 (2003) 175-198
177. Mulder W., Strijkers G., Griffioen A., et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem 15 (2004) 799-806
178. Pirollo K., Dagata J., Wang P., et al. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging 5 (2006) 41-52
179. 129Xe MRI using gas-filled liposomes. Acad Radiol 9 suppl 1 (2002) S270-S274
180. Weissig V., Babich J., and Torchilin V. Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. Colloids Surf B Biointerfaces 18 (2000) 293-299